Pharmacologic Management of Pediatric Paroxysmal Sympathetic Hyperactivity in North America
OBJECTIVE Describe pharmacological management approaches to pediatric paroxysmal sympathetic hyperactivity (PSH) among North American pediatric attending physicians. PARTICIPANTS AND METHODS Cross-sectional web-based survey of pediatric attending physicians conducted from March to August 2023. The questionnaire examined PSH medication utilization and preferences, subspecialty responsibilities for managing PSH, and the influence of patient age on medication selection. Descriptive statistics summarize PSH medication utilization and rank-order preferences. Chi-square analyses examined relationships between physician specialty and medication selection. RESULTS Among 295 respondents (33% palliative care, 23% neurology, 18% complex care, 17% physiatry), considerable heterogeneity in PSH pharmacotherapy approaches was observed. The most used abortive PSH medications were gamma-aminobutyric acid A (GABA-A) agonists (86%), alpha-2 agonists (79%), and opioids (49%). Leading preventive PSH medications included alpha-2 agonists (90%), gabapentinoids (89%), and beta-blockers (66%). Top-ranked medications for abortive management were alpha-2 agonists, GABA-A agonists, and non-opioid analgesics; and gabapentinoids, alpha-2 agonists, and beta-blockers for preventive management. While physiatrists and neurologists were most frequently identified as primary managers of PSH at participants’ home institutions, several other specialties (including multidisciplinary models) were reported as well. We observed significant differences in utilization of alpha-2 agonists, opioids, dopamine agonists, and beta-blockers across subspecialties (all P < .05). Patient age influenced medication selection among 41% of our sample. CONCLUSIONS Pharmacologic management of pediatric PSH currently lacks clinical consensus and varies significantly based on physician subspecialty. Our findings underscore the need for focused research efforts to identify optimal treatment strategies and develop standardized and evidence-based management guidelines.
Authors
- Hitoshi G. Koshiya (ORCID: https://orcid.org/0000-0002-6618-0935)
- Laura A. Kirkpatrick (ORCID: https://orcid.org/0000-0002-8259-5997)
- Julie Hauer (ORCID: https://orcid.org/0000-0003-2881-5917)
- Justin Yu
- Alyssa Breaugh-Shoup
Institutions
- Boston Children's Hospital (US)
- University of Pittsburgh (US)
- UPMC Health System (US)
- Duke Medical Center (US)
- Children's Hospital of Pittsburgh (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Hospital Pediatrics
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1542/hpeds.2026-009531
- Primary Topic
- Cerebral Palsy and Movement Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00